reports
Longeveron® Issues Letter to Shareholders Highlighting Corporate Strat...
Longeveron® Issues Letter to Shareholders Highlighting Corporate Strategy, Recent Progress and Key Priorities and Goals for 2025 MIAMI, April 22, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that the Company’s CEO, Wa’el Hashad, issued the following letter to Longeveron shareholders. Dear Fellow Shareholders, Twenty twenty-four was a year of execution for Longeveron. We made significant progress advancing Longeveron’s foun...
- Wedbush Research
XNCR XENCOR INC.
XENE XENON PHARMACEUTICALS INC
VYGR VOYAGER THERAPEUTICS INC.
RARE ULTRAGENYX PHARMACEUTICAL INC.
PRGS PROGRESS SOFTWARE CORPORATION
NVCR NOVOCURE LTD.
NBIX NEUROCRINE BIOSCIENCES INC.
MNRO MONRO INC
KURA KURA ONCOLOGY INC.
GERN GERON CORP.
FATE FATE THERAPEUTICS INC
CTMX CYTOMX THERAPEUTICS INC.
CMRX CHIMERIX INC
BPMC BLUEPRINT MEDICINES CORP.
BMRN BIOMARIN PHARMACEUTICAL INC.
BIIB BIOGEN INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
ARDX ARDELYX INC
FRX_CN FENNEC PHARMACEUTICALS
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
MRSN MERSANA THERAPEUTICS
ISR ISORAY
APLS APELLIS PHARMACEUTICALS
DNLI DENALI THERAPEUTICS INC
RCUS ARCUS BIOSCIENCES
SRRK SCHOLAR ROCK HOLDING CORPORATION
KNSA KINIKSA PHARMACEUTICALS
REPL REPLIMUNE GROUP
ARVN ARVINAS HOLDING
YMAB Y-MABS THERAPEUTICS
STRO SUTRO BIOPHARMA
SAFE SAFEHOLD INC.
STOK STOKE THERAPEUTICS
IGMS IGM BIOSCIENCES
SWTX SPRINGWORKS THERAPEUTICS
IDYA IDEAYA BIOSCIENCES
PASG PASSAGE BIO
BDTX BLACK DIAMOND THERAPEUTICS
ACET ADICET BIO INC
KROS KEROS THERAPEUTICS
ITOS ITEOS THERAPEUTICS
ZNTL ZENTALIS PHARMACEUTICALS
LRMR LARIMAR THERAPEUTICS INC
PRAX PRAXIS PRECISION MEDICINES
TVTX TRAVERE THERAPEUTICS INC
VRDN VIRIDIAN THERAPEUTICS INC
DAWN DAY ONE BIOPHARMACEUTICALS INC
ELEV ELEVATION ONCOLOGY
ATXS ASTRIA THERAPEUTICS INC
AVTE AEROVATE THERAPEUTICS INC
GMTX GEMINI THERAPEUTICS INC
VIGL VIGIL NEUROSCIENCE INC
TYRA TYRA BIOSCIENCES INC
EWTX EDGEWISE THERAPEUTICS INC
APGE APOGEE THERAPEUTICS INC
- Jay Kornreich
- Richard Anderson
Longeveron® Announces Positive Type B Meeting with U.S. FDA Regarding ...
Longeveron® Announces Positive Type B Meeting with U.S. FDA Regarding Pathway to BLA for Laromestrocel (Lomecel-BTM) in Alzheimer’s Disease Planned single, pivotal Phase 2/3 clinical trial, if positive, acceptable for Biological License Application (BLA) submission for Alzheimer’s diseaseAlignment with FDA on proposed trial study design, population and endpointsInitiation of planned pivotal Phase 2/3 clinical trial anticipated in 2H 2026, contingent upon obtaining non-dilutive funding and/or partnering supportLaromestrocel (Lomecel-B™) has received FDA Regenerative Medicine Advanced Therapy...
Longeveron® Announces Nature Medicine Publication of Results of Phase ...
Longeveron® Announces Nature Medicine Publication of Results of Phase 2a Clinical Trial Evaluating Laromestrocel (Lomecel-B™) in Alzheimer’s Disease Phase 2a results demonstrated laromestrocel (Lomecel-B™) improved cognitive function, quality of life, and brain volume in the treatment of mild Alzheimer’s diseaseThis encouraging clinical trial data adds to the body of evidence supporting the safety of single and multiple doses of laromestrocel (Lomecel-B™) treatment for mild Alzheimer’s disease and provides indications of efficacy in combating decline of brain volume and potentially cognitiv...
Longeveron® to Present at the 37th Annual Roth Conference
Longeveron® to Present at the 37th Annual Roth Conference MIAMI, March 05, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in the 37th Annual Roth Conference taking place March 17-18, 2025. Details for the Company’s fireside chat: Date:Tuesday, March 18, 2025 Time:9:00 – 9:25 a.m. PT The webcast for this conference presentation may be accessed at the “” section of the Company’s website. A replay of the we...
Longeveron® Announces Full-Year 2024 Financial Results and Provides Bu...
Longeveron® Announces Full-Year 2024 Financial Results and Provides Business Update Pivotal Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B™ (laromestrocel) in Hypoplastic Left Heart Syndrome (HLHS), a rare pediatric disease and orphan-designated indication, has achieved more than 90% enrollment and is expected to complete enrollment in the second quarter of 2025Lomecel-B™ Biological License Application (BLA) submission for full traditional approval anticipated in 2026, if ELPIS II is successfulFDA meeting anticipated late in first quarter of 2025 to discuss possible development pat...
Longeveron® to Report Full Year 2024 Financial Results and Host Confer...
Longeveron® to Report Full Year 2024 Financial Results and Host Conference Call on February 28, 2025 MIAMI, Feb. 21, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will report full-year 2024 financial results and provide a business update on Friday, February 28, 2025 after the U.S. financial markets close. The Company will host a conference call and webcast the same day at 4:30 p.m. ET. Conference Call and Web...
Longeveron® Announces World Health Organization Approval of “laromestr...
Longeveron® Announces World Health Organization Approval of “laromestrocel” as International Non-proprietary Name for Stem Cell Therapy Lomecel-B™ Cellular therapy Lomecel-B™ has been granted an International Non-proprietary Name (INN) of “laromestrocel” on the INN List issued by the World Health Organization (WHO)Lomecel-B™ is a proprietary, scalable, allogeneic cellular therapy being evaluated in Alzheimer’s disease and hypoplastic left heart syndrome (HLHS), a rare pediatric disease and orphan indicationLomecel-B™ first cellular therapeutic candidate to receive U.S. FDA Regenerative Medi...
Longeveron to Present at the Emerging Growth Virtual Conference on Feb...
Longeveron to Present at the Emerging Growth Virtual Conference on February 19, 2025 MIAMI, Feb. 14, 2025 (GLOBE NEWSWIRE) -- (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in the Emerging Growth Virtual Conference taking place February 18-19, 2025. Details for the Company’s presentation: Date:February 19, 2025Time:3:10 – 3:20 p.m. ET The webcast for this conference presentation may be accessed at the “” section of the Co...
- Wedbush Research
XNCR XENCOR INC.
WEN WENDY'S COMPANY
WDC WESTERN DIGITAL CORPORATION
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
TSLA TESLA INC
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
QLYS QUALYS INC.
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
NBIX NEUROCRINE BIOSCIENCES INC.
MU MICRON TECHNOLOGY INC.
MCD MCDONALD'S CORPORATION
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
EBAY EBAY INC.
DENN DENNY'S CORPORATION
CXW CORECIVIC INC.
CRM SALESFORCE.COM INC.
AXTI AXT INC.
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
PTGX PROTAGONIST THERAPEUTICS
ANAB ANAPTYSBIO INC.
ARGX ARGENX ADS
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
IBM INTERNATIONAL BUSINESS MACHINES CORPORATION
EPRT ESSENTIAL PROPERTIES REALTY TRUST
SAFE SAFEHOLD INC.
PINS PINTEREST INC. CLASS A
CRWD CROWDSTRIKE HOLDINGS INC. CLASS A
IGMS IGM BIOSCIENCES
SMCI SUPER MICRO COMPUTER
ORIC INC.
FUBO ORIC PHARMACEUTICALS
DASH FUBOTV
ABNB DOORDASH
VRDN AIRBNB INC. CLASS A
RBLX VIRIDIAN THERAPEUTICS INC
STX ROBLOX
TTD SEAGATE TECHNOLOGY HLDGS PLC
GFS THE TRADE DESK
NTST INC.
ARTV GLOBALFOUNDRIES INC
BROS NETSTREIT CORP
DNTH ARTIVA BIOTHERAPEUTICS INC
DUTCH BROS INC
DIANTHUS THERAPEUTICS INC
- Jay Kornreich
- Richard Anderson
- Wedbush Research
DEI DOUGLAS EMMETT INC
WFC WELLS FARGO & COMPANY
WDC WESTERN DIGITAL CORPORATION
UMH UMH PROPERTIES INC.
UDR UDR INC.
TRNO TERRENO REALTY CORPORATION
STAG STAG INDUSTRIAL INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
SBRA SABRA HEALTH CARE REIT INC.
RHP RYMAN HOSPITALITY PROPERTIES INC.
REXR REXFORD INDUSTRIAL REALTY INC.
PEGA PEGASYSTEMS INC.
PEB PEBBLEBROOK HOTEL TRUST
OHI OMEGA HEALTHCARE INVESTORS INC.
OFC CORPORATE OFFICE PROPERTIES TRUST
O REALTY INCOME CORPORATION
NRZ NEW RESIDENTIAL INVESTMENT CORP.
NHI NATIONAL HEALTH INVESTORS INC.
MAA MID-AMERICA APARTMENT COMMUNITIES INC.
LTC LTC PROPERTIES INC.
IMAX IMAX CORPORATION
GOOGL ALPHABET INC. CLASS A
GLPI GAMING AND LEISURE PROPERTIES INC.
GERN GERON CORP.
FR FIRST INDUSTRIAL REALTY TRUST INC.
ESS ESSEX PROPERTY TRUST INC.
EQR EQUITY RESIDENTIAL
EGP EASTGROUP PROPERTIES INC.
CTRE CARETRUST REIT INC
CRM SALESFORCE.COM INC.
CPT CAMDEN PROPERTY TRUST
CHKP CHECK POINT SOFTWARE TECHNOLOGIES LTD.
CAKE CHEESECAKE FACTORY INCORPORATED
BXP BOSTON PROPERTIES INC.
AVB AVALONBAY COMMUNITIES INC.
APLE APPLE HOSPITALITY REIT INC
HST HOST HOTELS & RESORTS INC.
CMA COMERICA INCORPORATED
PK PARK HOTELS & RESORTS INC.
PLYM PLYMOUTH INDUSTRIAL REIT INC.
VTR VENTAS INC.
VICI VICI PROPERTIES INC
MDB MONGODB INC. CLASS A
AMZN AMAZON.COM INC.
AAPL APPLE INC.
MSFT MICROSOFT CORPORATION
EPRT ESSENTIAL PROPERTIES REALTY TRUST
SAFE SAFEHOLD INC.
PEAK HEALTHPEAK PROPERTIES INC.
PLTR PALANTIR TECHNOLOGIES
WOOF PETCO HEALTH AND WELLNESS
AIRC APARTMENT INCOME REIT
CSR CENTERSPACE
SNOW SNOWFLAKE INC. CLASS A
RBLX ROBLOX
NTST NETSTREIT CORP
HR HEALTHCARE TRUST OF AMERICA INC.
EWTX EDGEWISE THERAPEUTICS INC
BNL BROADSTONE NET LEASE INC
WAL-US WESTERN ALLIANCE BANCORPORATION
ESTC-US ELASTIC INC.
- Jay Kornreich
- Richard Anderson
UMH UMH PROPERTIES INC.
UDR UDR INC.
TRNO TERRENO REALTY CORPORATION
STAG STAG INDUSTRIAL INC.
SBRA SABRA HEALTH CARE REIT INC.
RHP RYMAN HOSPITALITY PROPERTIES INC.
REXR REXFORD INDUSTRIAL REALTY INC.
PEB PEBBLEBROOK HOTEL TRUST
OHI OMEGA HEALTHCARE INVESTORS INC.
OFC CORPORATE OFFICE PROPERTIES TRUST
O REALTY INCOME CORPORATION
NHI NATIONAL HEALTH INVESTORS INC.
MAA MID-AMERICA APARTMENT COMMUNITIES INC.
LTC LTC PROPERTIES INC.
WELL WELLTOWER INC.
GLPI GAMING AND LEISURE PROPERTIES INC.
FR FIRST INDUSTRIAL REALTY TRUST INC.
ESS ESSEX PROPERTY TRUST INC.
EQR EQUITY RESIDENTIAL
EGP EASTGROUP PROPERTIES INC.
CTRE CARETRUST REIT INC
CPT CAMDEN PROPERTY TRUST
BXP BOSTON PROPERTIES INC.
AVB AVALONBAY COMMUNITIES INC.
ARE ALEXANDRIA REAL ESTATE EQUITIES INC.
APLE APPLE HOSPITALITY REIT INC
HST HOST HOTELS & RESORTS INC.
PK PARK HOTELS & RESORTS INC.
PLYM PLYMOUTH INDUSTRIAL REIT INC.
VTR VENTAS INC.
VICI VICI PROPERTIES INC
EPRT ESSENTIAL PROPERTIES REALTY TRUST
SAFE SAFEHOLD INC.
PEAK HEALTHPEAK PROPERTIES INC.
CSR CENTERSPACE
NTST NETSTREIT CORP
HR HEALTHCARE TRUST OF AMERICA INC.
BNL BROADSTONE NET LEASE INC
Longeveron to Present at Biotech Showcase 2025
Longeveron to Present at Biotech Showcase 2025 MIAMI, Dec. 18, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that Wa’el Hashad, Chief Executive Officer, will give a corporate presentation at Biotech Showcase, being held January 13-15, 2025. Details for the Company’s presentation: Date:Tuesday, January 14, 2025Time:4:00 – 4:30 p.m. PT The webcast for this conference presentation may be accessed at the “” section of the Company’...
Longeveron to Present at the Emerging Growth Virtual Conference on Dec...
Longeveron to Present at the Emerging Growth Virtual Conference on December 5, 2024 MIAMI, Dec. 02, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it will participate in the Emerging Growth Virtual Conference taking place December 4-5, 2024. Details for the Company’s presentation: Date:December 5, 2024Time:12:00 – 12:30 p.m. ET The webcast for this conference presentation may be accessed at the “” section of the Company’s ...
- Jay Kornreich
- Richard Anderson
- Sydnie Rohme
STAG STAG INDUSTRIAL INC.
SBRA SABRA HEALTH CARE REIT INC.
RHP RYMAN HOSPITALITY PROPERTIES INC.
OHI OMEGA HEALTHCARE INVESTORS INC.
O REALTY INCOME CORPORATION
NHI NATIONAL HEALTH INVESTORS INC.
MAA MID-AMERICA APARTMENT COMMUNITIES INC.
GLPI GAMING AND LEISURE PROPERTIES INC.
ESS ESSEX PROPERTY TRUST INC.
EGP EASTGROUP PROPERTIES INC.
CTRE CARETRUST REIT INC
APLE APPLE HOSPITALITY REIT INC
PK PARK HOTELS & RESORTS INC.
PLYM PLYMOUTH INDUSTRIAL REIT INC.
VICI VICI PROPERTIES INC
EPRT ESSENTIAL PROPERTIES REALTY TRUST
SAFE SAFEHOLD INC.
PEAK HEALTHPEAK PROPERTIES INC.
NTST NETSTREIT CORP
HR HEALTHCARE TRUST OF AMERICA INC.
BNL BROADSTONE NET LEASE INC
- Wedbush Research
TRNO TERRENO REALTY CORPORATION
STAG STAG INDUSTRIAL INC.
SBRA SABRA HEALTH CARE REIT INC.
RHP RYMAN HOSPITALITY PROPERTIES INC.
OHI OMEGA HEALTHCARE INVESTORS INC.
O REALTY INCOME CORPORATION
NHI NATIONAL HEALTH INVESTORS INC.
MAA MID-AMERICA APARTMENT COMMUNITIES INC.
GOOGL ALPHABET INC. CLASS A
GLPI GAMING AND LEISURE PROPERTIES INC.
ETSY ETSY INC.
ESS ESSEX PROPERTY TRUST INC.
EGP EASTGROUP PROPERTIES INC.
CTRE CARETRUST REIT INC
CRM SALESFORCE.COM INC.
CMRX CHIMERIX INC
APLE APPLE HOSPITALITY REIT INC
SLM SLM CORP
NTLA INTELLIA THERAPEUTICS INC.
PK PARK HOTELS & RESORTS INC.
PLYM PLYMOUTH INDUSTRIAL REIT INC.
VICI VICI PROPERTIES INC
AMZN AMAZON.COM INC.
MSFT MICROSOFT CORPORATION
ESTC ELASTIC N.V.
EPRT ESSENTIAL PROPERTIES REALTY TRUST
SAFE SAFEHOLD INC.
PEAK HEALTHPEAK PROPERTIES INC.
PLTR PALANTIR TECHNOLOGIES
SNOW SNOWFLAKE INC. CLASS A
UPST UPSTART HOLDINGS
NTST NETSTREIT CORP
HR HEALTHCARE TRUST OF AMERICA INC.
PGY PAGAYA TECHNOLOGIES LTD
BNL BROADSTONE NET LEASE INC
Longeveron® Announces Third Quarter 2024 Financial Results and Provide...
Longeveron® Announces Third Quarter 2024 Financial Results and Provides Business Update Phase 2b clinical trial (ELPIS II) evaluating Lomecel-B™ in rare pediatric disease HLHS has achieved more than 80% enrollmentPositive Type C meeting with U.S. FDA confirmed ELPIS II is pivotal and, if positive, acceptable for Biological License Application (BLA) submission for full traditional approvalPositive data from the Phase 2a clinical trial (CLEAR MIND) evaluating Lomecel-B™ in Alzheimer’s disease presented in Featured Research Oral Presentation at Alzheimer’s Association International Conference®...
Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP o...
Longeveron® Appoints Devin Blass as Chief Technology Officer and SVP of Chemistry, Manufacturing and Controls (CMC) MIAMI, Nov. 11, 2024 (GLOBE NEWSWIRE) -- (NASDAQ: LGVN), a clinical stage regenerative medicine biotechnology company developing cellular therapies for life-threatening and chronic aging-related conditions, today announced that it has appointed Devin Blass as Chief Technology Officer (CTO) and Senior Vice President of Chemistry, Manufacturing, and Controls (CMC), effective December 2, 2024. In this role, he will lead the Company’s technological and manufacturing strategies....
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.